Nexeon acquires licence to 86 IoT patents and receives ISO 13485 certification

Nexeon MedSystems, a company that provides deep learning systems for implantable medical devices has licensed a portfolio of patents from Marathon Patent Group.

The portfolio of 86 patents originated from Siemens AG, protects innovations in the Internet-of-Things (IoT) space, which can be described as the interconnection via the internet of computing devices embedded in everyday objects, enabling them to send and receive data. This technology can be used in a variety of medical device applications, notably in hospitals, nursing facilities, or patients’ homes.

“The data gathered in these IoT systems can be utilised to help improve the programming for implantable devices,” said Nexeon chairman and CEO Will Rosellini. “An average patient with a chronic disease typically takes more than five different medications everyday, most of which need to be taken at different times of the day and have specific dietary recommendations to accompany the dosages.

This same patient is typically demonstrating symptoms associated with cognitive, psychiatric, and motor disorders as well. The promise of keeping the device in the right therapeutic range with data from the IoT is extraordinary.”

The portfolio’s subject matter is directed toward self-healing control networks for building automation systems in the hospital and the home. The patents are relevant to wireless mesh networks for use in the IoT and enable simple commissioning, application level security, simplified bridging, and end-to-end IP security.

There is a growing trend in electrophysiology toward remote home-monitoring of implantable cardioverter defibrillators (ICDs), cardiac resynchronisation therapy (CRT) devices, pacemakers, and implantable cardiac monitors (ICMs).

Will Rosellini

By enabling more automated device management and data integration, advanced devices could enable the quantified self. The company has engaged Battelle to define the data structures and cybersecurity protocols needed to provide the framework for deep learning.

“Siemens is one of the most innovative firms in the world,” Rosellini continued. “Integrating their network innovation with our patient-specific solutions will substantially reduce the burden of chronic disease. By addressing this unmet need, we will create tremendous value in the form of better, faster care with fewer in-office visits required, easier access to more accurate patient information, and decreased complications and undesired side effects due to more precise therapy and better monitoring.”

ISO 13485 cetification

Liege-based Nexeon Medsystems Belgium, SPRL has received certification from DEKRA CERTIFICATION B.V. that the company complies with the European requirements of ISO 13485 and EN ISO 13485 for a comprehensive quality management system for the design and manufacture of the company’s implantable neurostimulation system.

Company management has described this as a critical milestone on the path to launching its neuromodulation platform, both for its leading indication in deep brain stimulation (DBS) for Parkinson’s disease as well as follow-on products for other neurological diseases.

“Nexeon has an ongoing commitment to delivering the most advanced and highest quality neuromodulation devices for the treatment of neurologic diseases,” said Nexeon VP of Quality Dr. Stéphane Béfahy. He continued, “We are deliberately investing in our design and production processes in preparation for the commercial launch of our first product as well as the delivery of products for third-party device contracts that are currently in progress.”

Since 2013, the team at Nexeon Belgium has received both research grants and commercial contracts to advance the development and manufacture of its neuromodulation platform and related peripherals. The grants include a €3.4 million(US$ 3.72 million) funded consortium partnership in alignment with Minister Marcourt’s e-health initiative for the Walloon Region in Belgium.

The company’s most notable commercial contract is a multi-year agreement with Galvani Bioelectronics, a joint venture of Google/Verily and GlaxoSmithKline (GSK). After an exhaustive search, Galvani selected Nexeon’s platform to conduct its novel preclinical work. The contract is ongoing as Galvani exercised its option to enter the second phase last year.

Comment on this article below or via Twitter: @IoTNow_ OR @jcIoTnow

FEATURED IoT STORIES

9 IoT applications that will change everything

Posted on: September 1, 2021

Whether you are a future-minded CEO, tech-driven CEO or IT leader, you’ve come across the term IoT before. It’s often used alongside superlatives regarding how it will revolutionize the way you work, play, and live. But is it just another buzzword, or is it the as-promised technological holy grail? The truth is that Internet of

Read more

Which IoT Platform 2021? IoT Now Enterprise Buyers’ Guide

Posted on: August 30, 2021

There are several different parts in a complete IoT solution, all of which must work together to get the result needed, write IoT Now Enterprise Buyers’ Guide – Which IoT Platform 2021? authors Robin Duke-Woolley, the CEO and Bill Ingle, a senior analyst, at Beecham Research. Figure 1 shows these parts and, although not all

Read more

CAT-M1 vs NB-IoT – examining the real differences

Posted on: June 21, 2021

As industry players look to provide the next generation of IoT connectivity, two different standards have emerged under release 13 of 3GPP – CAT-M1 and NB-IoT.

Read more

IoT and home automation: What does the future hold?

Posted on: June 10, 2020

Once a dream, iot home automation is slowly but steadily becoming a part of daily lives around the world. In fact, it is believed that the global market for smart home automation will reach $40 billion by 2020.

Read more
RECENT ARTICLES

Yellowfin explores the future of data storytelling and reveals the impact narrative and automation will have on business analytics

Posted on: October 27, 2021

London. 27 October, 2021 – Yellowfin, the analytics vendor that combines action-based dashboards, automated discovery, and powerful data storytelling, launches a white paper exploring ‘The Future of Data Storytelling: how narrative and automation will redefine the next decade of analytics’, offering valuable insight to organisations on the power and potential of future augmented and automated

Read more

Renesas and wolfSSL enable ready-to-use IoT security solutions based on embedded TLS stack

Posted on: October 27, 2021

TOKYO, Japan and EDMONDS. Washington, October 27, 2021 ― Renesas Electronics Corporation, a supplier of advanced semiconductor solutions, and wolfSSL, a provider of embedded security solutions, announced a multi-year licensing agreement whereby customers of Renesas’ 32-bit MCU offerings can obtain a free commercial license for the wolfSSL TLS (Transport Layer Security) stack with integrated Renesas hardware

Read more